The genomic simplicity of differentiated cancers derived from thyroid follicular cells offers
unique insights into how oncogenic drivers impact tumour phenotype. Essentially, the main …

Thyroid cancer is a common endocrine malignancy. There has been exciting progress in
understanding its molecular pathogenesis in recent years, as best exemplified by the …

In recent years, the T1799A B-type Raf kinase (BRAF) mutation in thyroid cancer has
received enthusiastic investigation, and significant progress has been made toward …

Advanced human thyroid cancers, particularly those that are refractory to treatment with
radioiodine (RAI), have a high prevalence of BRAF (v-raf murine sarcoma viral oncogene …

Objective: To examine the prevalence of BRAF mutation among thyroid cancer histologic
subtypes and determine the association of BRAF mutation with indicators of poor prognosis …

Thyroid cancers are infiltrated with tumor-associated macrophages (TAMs), yet their role in
cancer progression is not known. The objectives of this study were to characterize the …

Context: Because very few studies have examined the correlation between BRAF mutations
and clinicopathological features of papillary thyroid carcinoma (PTC), we analyzed here a …

Context: Five to 10% of patients with differentiated thyroid cancers (DTC) develop invasive
and/or distant metastatic disease that is marginally improved with standard therapies …

The activating mutation BRAFV600E is a frequent genetic event in papillary thyroid
carcinomas (PTC) that predicts a poor prognosis, leading to loss of sodium/iodide symporter …

Papillary thyroid cancer (PTC) is a common endocrine malignancy that frequently harbors
the oncogenic T1799A BRAF mutation. As a novel prognostic molecular marker, this …